Compare ELE & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELE | SPTX |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2025 | 2026 |
| Metric | ELE | SPTX |
|---|---|---|
| Price | $20.43 | $21.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | ★ 289.5K | 143.6K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $109.25 | N/A |
| Revenue Next Year | $16.14 | N/A |
| P/E Ratio | $255.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.01 | $17.59 |
| 52 Week High | $26.96 | $28.38 |
| Indicator | ELE | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.39 |
| Support Level | N/A | $18.72 |
| Resistance Level | N/A | $22.75 |
| Average True Range (ATR) | 0.00 | 1.85 |
| MACD | 0.00 | -0.29 |
| Stochastic Oscillator | 0.00 | 32.11 |
Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments. It is the result of the strategic merger of Elemental Altus Royalties and EMX Royalty Corporation together creating a mid-tier gold-focused royalty company with the scale, diversification, and cash flow. Geographically, the company generates revenue from North America, South America, Europe, Australia and Africa.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.